secwatch.observer — SEC 8-K summary
======================================

Issuer:     OCULAR THERAPEUTIX, INC (OCUL)
CIK:        0001393434
Form:       8-K
Filed at:   2023-05-08T23:59:59+00:00
Accession:  0001104659-23-057139
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocular Therapeutix Q1 net loss widens to $30.3M; DEXTENZA rev up 6% to $13.2M
-----------------------------------------------------------------------------

- Net loss of $30.3M ($0.39/share) vs $12.5M ($0.16/share) in Q1 2022; includes $6.6M non-cash derivative fair value charge.
- DEXTENZA net product revenue $13.2M (+6% YoY); total net revenue $13.4M. FY2023 revenue guidance reiterated at $55-60M.
- Cash & equivalents $79.0M at Mar 31, 2023 (down from $102.3M); cash runway to mid-2024 excluding planned OTX-TKI trials.
- OTX-TKI wet AMD Phase 1 12-month data to be presented June 2023; potentially start pivotal trial in Q3 2023.
- OTX-TIC glaucoma Phase 2 enrolling; top-line data expected Q4 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1393434/000110465923057139/0001104659-23-057139-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1393434/000110465923057139/tm2314977d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-057139

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer